<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g302" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-302.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
                <a href="#nav-panel" class="ui-btn ui-icon-bars ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-297.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-299.html" >Pelvic Inflammatory Disease</a><span class="carrot"> > </span>
                    <a href="lv-302.html" >Treatment</a><span class="carrot"> > </span>
                    <a href="lv-302.html" >Oral Treatment</a><span class="carrot"> > </span>Overview
            </div>
            </br><h3 class="sgc-1" id="sigil_toc_id_302">
 Oral Treatment
</h3>
<p>
 Outpatient, oral therapy can be considered for women with mild-to-moderately severe acute PID, because the clinical outcomes among women treated with oral therapy are similar to those treated with parenteral therapy (390). The following regimens provide coverage against the frequent etiologic agents of PID. Patients who do not respond to oral therapy within 72 hours should be reevaluated to confirm the diagnosis and should be administered parenteral therapy on either an outpatient&nbsp;or inpatient basis.
</p>
<p>

        <div id="table">
            <div id="regimen_header">Recommended Oral Regimens
            </div>
            <hr/>
            <span class="regimen_text">Ceftriaxone 250 mg IM in a single dose
            <div id="or">PLUS</div>Doxycycline 100 mg orally twice a day for 14 days
            <div id="or">WITH or WITHOUT</div>Metronidazole* 500 mg orally twice a day for 14 days
            <div id="or">
                <hr/>OR
                <hr/>
            </div>Cefoxitin 2 g IM in a single dose and Probenecid, 1 g orally administered concurrently in a single dose
            <div id="or">PLUS</div>Doxycycline 100 mg orally twice a day for 14 days
            <div id="or">WITH or WITHOUT</div>Metronidazole* 500 mg orally twice a day for 14 days
            <div id="or">
                <hr/>OR
                <hr/>
            </div>Other parenteral third-generation cephalosporin (e.g., ceftizoxime or cefotaxime)
            <div id="or">PLUS</div>Doxycycline 100 mg orally twice a day for 14 days
            <div id="or">WITH or WITHOUT</div>Metronidazole* 500 mg orally twice a day for 14 days
            </span>

            <hr/>
                <p class="regimen_footer_text">* Adding metronidazole also will effectively treat BV, which is frequently associated with PID.</p>
        </div>
 <br/>
</p>
<p>
 The optimal choice of a cephalosporin is unclear; although cefoxitin has better anaerobic coverage, ceftriaxone has better coverage against
 <i>
  N. gonorrhoeae
 </i>
 . A single dose of cefoxitin is effective in obtaining short-term clinical response in women who have PID. However, the theoretical limitations in coverage of anaerobes by recommended cephalosporin antimicrobials might require the addition of metronidazole to the treatment regimen (393). Adding metronidazole also will effectively treat BV, which is frequently associated with PID. No data have been published regarding the use of oral cephalosporins for the treatment of PID.
</p>

            </div>
        <div data-role="panel" data-display="push" data-theme="b" id="nav-panel">
            <ul data-role="listview">
                <li data-icon="delete"><a href="#" data-rel="close">Close menu</a></li>
                <li><a href="../conditions/c0-clv.html">Condition Quick Pick</a></li>
                <li><a href="../guidelines/lv-0.html">Full STD Tx Guidelines</a></li>
                <li><a href="../page/hx-pdf.html">Taking a Sexual Hx PDF</a></li>
                <li><a href="../terms/1.html">Terms and Abbreviations</a></li>
                <li><a href="../refs/lv-0.html">References</a></li>
                <li><a href="../page/about_us.html">About Us</a></li>
            </ul>
        </div><!-- /panel -->
    
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>
    